Acoramidis Shows Durable Survival Benefit in ATTR-CM Through 54 Months

Overview

• Results from the ATTRibute-CM open-label extension, published Monday in JAMA Cardiology and presented at ACC 2026, link early and continuous acoramidis to fewer deaths and first cardiovascular hospitalizations through month 54.
• Patients who stayed on acoramidis had a 45% lower risk of all-cause death, a 49% lower risk of cardiovascular death, and a 47% lower risk of a first cardiovascular hospitalization compared with those who started the drug later.
• The extension followed 389 people with transthyretin amyloid cardiomyopathy, a progressive protein–deposit heart disease, with 263 continuing acoramidis and 126 switching from placebo at month 30 over a median of 53.2 months.
• Biomarkers and function favored early therapy, with stable NT-proBNP, larger rises in serum transthyretin, a slower drop in six-minute walk distance, and preserved heart-failure health status, while late starters stabilized or improved after switching.
• No new long-term safety concerns were reported, but interpretation is limited by the open-label design, baseline imbalances, heavy background heart-failure therapy use, and study funding and author ties to BridgeBio.